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biochemical analysis of the underlying bone tissue has provided
important information for treatment of osteoarthritis. In this study, we
determined the potential role of formononetin, a phytoestrogen isolated
from Astragalus membranaceus to alter the expression of metabolic
markers and cytokine production of human normal osteoblasts (Obs)
and osteoarthritis subchondral osteoblasts (OA Obs).
Methods: Human OA Obs and normal Obs were cultured for 3 days,
7 days or 14 days in presence medium only or were treated with various
doses of formononetin. Cells were analyzed for viability by WST-8 assay,
alkaline phosphatase (ALP) activity, osteogenic markers (osteocalcin
(OCN) and type I collagen (Col I)) and cytokines (interleukin-6 (IL-6),
vascular endothelial growth factor (VEGF), bone morphogenic protein-2
(BMP-2)). The level of IL-6, VEGF, BMP-2, OCN and Col I was increased
in OA Obs compared with normal Obs.
Results: Formononetin dose-dependently decreased ALP, IL-6, VEGF,
BMP-2, OCN and Col I in OA Obs, while markedly increased ALP,
VEGF, BMP-2, OCN and Col I in normal Obs. Interestingly, formononetin
markedly increased the expression of VEGF and BMP-2 for 3 days
of culture and signiﬁcantly increased OCN and Col I at 14 days in
human normal Obs. The remodeling effect of formononetin on osteogenic
markers and cytokines of inﬂammatory mediators was more striking in
OA Obs as well.
Conclusions: These results could suggest that formononetin has biphasic
positive effects on normal Obs and OA Obs by modifying their biological
synthetic capacities.
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Purpose: Oral nonsteroidal anti-inﬂammatory drugs (NSAIDs) are
effective for the treatment of osteoarthritis (OA), but their chronic
use is associated with serious gastrointestinal (GI), cardiovascular, and
potentially other systemic adverse events (AEs). Diclofenac topical
solution (TDiclo) has demonstrated efﬁcacy similar to oral diclofenac
(ODiclo) in randomized, double-blind, clinical trials in OA of the knee,
with fewer GI AEs. The incidence of GI AEs occurring with TDiclo in
patients in an ofﬁce setting was analyzed using safety data from a
Canadian compassionate-use treatment program of TDiclo for OA.
Methods: In this multicenter, open-label, open-ended, compassionate-
use, Phase 3 study, patients with physician-diagnosed OA were instructed
to apply 5 drops (small joint, eg, knuckle), 20 drops (medium joint, eg,
wrist), or 40 drops (large joint, eg, knee) of TDiclo to the affected joint
4 times daily in an uncontrolled, real-world setting. Follow-up safety
assessments were scheduled at 1, 3, 6, and 12 months, and yearly
thereafter. At each visit, patients were asked open-ended questions
regarding the onset and nature of any AE that occurred since the last
visit. It was at the patient’s discretion whether to contact the investigator
at the onset of an AE or wait until the next visit.
Results: A total of 4213 patients were evaluated. The duration of exposure
to TDiclo extended over 6–12 months in 12.4% and ≥12 months in 19.8%.
A GI AE occurred in 35 (0.8%) patients; the most frequently reported were
dyspepsia (0.4%), nausea (0.2%), and diarrhea (0.1%). A GI AE was listed
as a reason for study discontinuation in 23 patients (0.5%). None of the
GI AEs that occurred during the study were deemed by the investigator
to be related to TDiclo treatment.
Conclusions: In an uncontrolled ofﬁce-practice setting, the occurrence
of GI AEs in patients receiving TDiclo was low. No individual GI AE was
reported in >0.4% of patients, and few patients discontinued therapy
because of these events. The results of this open-label study demonstrate
that TDiclo is a well-tolerated therapeutic option for those patients who
wish to reduce their likelihood of experiencing the GI AEs that are
commonly associated with oral NSAIDs.
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Purpose: Randomized, double-blind trials of diclofenac topical solution
(TDiclo) in osteoarthritis (OA) of the knee have demonstrated efﬁcacy
similar to oral diclofenac, with fewer systemic adverse events (AEs). The
most common AEs occurring with TDiclo were application-site reactions.
To characterize these reactions in a clinical setting, safety data were
analyzed in patients who received TDiclo in a Canadian compassionate-
use treatment program for OA.
Methods: This was a multicenter, open-label, open-ended study
conducted in Canada. Patients with physician-diagnosed OA were
instructed to apply 5 drops (small joint, eg, knuckle), 20 drops (medium
joint, eg, wrist), or 40 drops (large joint, eg, knee) of TDiclo, 4 times
daily. Follow-up safety assessments were scheduled at 1, 3, 6, and
12 months, and yearly thereafter. At each visit, the investigator asked
the patient open-ended questions about any AE occurring since the
last visit, assessed the application site for signs of irritation and scored
it (0 = no visible reaction; 0.5 = equivocal response, itching burning
sensation, pruritus; 1 = mild erythema; 2 = intense erythema; 3 = intense
erythema with edema; and 4 = intense erythema with edema and
vesicular eruption).
Results: A total of 4213 patients were enrolled. The duration of exposure
to TDiclo extended over 6–12 months in 12.4% and ≥12 months in
19.8%. The most common AEs were application-site reactions in 112
of the 4213 patients (2.7%), which included rash (1.2%), dry skin (0.6%),
and pruritus (0.5%). Data regarding skin irritation score were available
for 1923 patients; of these, 1798 (93.5%) had a score of 0 (no visible
reaction), 59 (3.1%) had a score of 0.5 (equivocal response, itching,
burning sensation); and 48 (2.5%) had a score of 1 (mild erythema).
A score of 2 (intense erythema) was recorded in 7 (0.4%) and a score
of 3 (intense erythema with edema) in 6 (0.3%) patients; a score of 4
(intense erythema with edema and vesicular eruption) was recorded in
only 5 patients (0.3%). A total of 40 patients (0.9%) reported discontinuing
treatment because of an application-site reaction. No data were collected
on potential patient interventions such as emollients or creams.
Conclusions: Consistent with published controlled, clinical trials, the
most common AEs in individuals with OA treated with TDiclo in clinical
practice were skin-related. Their occurrence was low, and few patients
discontinued treatment because of these reactions. Given the risk of
systemic AEs associated with oral diclofenac, TDiclo has obvious potential
for the reduction of adverse effects.
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Purpose: Nitric oxide (NO), namely resulting from the activity of the
inducible nitric oxide synthase (iNOS) whose expression is increased
in osteoarthritic chondrocytes, is an important component of the
mechanisms that lead to cartilage degradation and inﬂammation,
the hallmarks of OA. Overexpression of iNOS and the subsequent
increased production of NO mediates, at least in part, the inhibition
of matrix synthesis and promotion of its degradation induced by pro-
inﬂammatory and catabolic cytokines, like interleukin-1b (IL-1), in
articular chondrocytes. Thus, inhibition of NO production and iNOS
expression are considered important targets for the development of anti-
osteoarthritic therapies. Essential oils are composed of a wide diversity
of hydrophobic low molecular weight compounds with favorable
pharmacokinetic properties that make them especially suited collections
for drug screening. Here we report results on a screening of the ability
of ﬁve essential oils to inhibit IL-1-induced iNOS expression and NO
production in human chondrocytes.
